U.S. Markets closed

Nascent Biotech, Inc. (NBIO)

Other OTC - Other OTC Delayed Price. Currency in USD
0.1980+0.0030 (+1.54%)
At close: 03:53PM EST

Nascent Biotech, Inc.

623 17th Street
Suite 4
Vero Beach, FL 32960
United States
612 961 5656

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Mr. Sean CarrickPres, CEO, Sec. & Director252kN/A1968
Mr. Lowell HoldenCFO, Chief Accounting Officer & Director180kN/A1943
Dr. Mark C. GlassyFounder & Chairman of Scientific Advisory BoardN/AN/A1952
Dr. Navpaul Singh M.D.Chief Medical ConsultantN/AN/AN/A
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nascent Biotech, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of various forms of cancer. It is developing Pritumumab, a drug to treat patients with brain cancer malignancies, such as glioblastoma and malignant astrocytoma, as well as epithelial cancers, including lung, breast, colon, brain, and pancreas cancer. In addition, the company is developing MultiPharm, a proprietary technology platform for cancer therapy, as well as diabetes, autoimmunity, and transplantation. Nascent Biotech, Inc. is based in Vero Beach, Florida.

Corporate Governance

Nascent Biotech, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.